Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks

OBJECTIVES We investigated whether improvement of endothelial dysfunction i n hypercholesterolemia can be achieved with short-term lipid-lowering thera py. BACKGROUND Impaired endothelium-dependent vasodilation plays a pivotal role in the pathogenesis of atherosclerosis and acute coronary syndromes. METHODS In a randomized, double-blind, placebo-controlled trial, we studied 37 patients (52 +/- 11 yrs) with low density lipoprotein cholesterol great er than or equal to 160 mg/d1(196 +/- 44 mg/dl) randomly assigned to either cerivastatin (0.4 mg/d) or placebo. Endothelium-dependent vasodilation of the forearm vasculature was measured by plethysmography and intra-arterial infusion of acetylcholine (ACh 12, 48 mug/min) and endothelium-independent vasodilation by intra-arterial infusion of nitroprusside (3.2, 12.8 mug/min ). RESULTS Low density lipoprotein cholesterol decreased after two weeks of tr eatment (cerivastatin -33 +/- 4% vs. placebo +2 +/- 4%, x +/- SEM, p < 0.00 1). Endothelium-dependent vasodilation improved after two weeks of therapy with cerivastatin compared with baseline (ACh 12 <mu>g/min: +22.3 +/- 5.2 v s. +11.2 +/- 1.9 ml/min/100 ml, p < 0.01; ACh 48 <mu>g/min: +31.2 +/- 6.3 v s, +19.1 +/- 3.1 ml/min/100 ml, p < 0.05). In contrast, changes in forearm blood how to ACh were similar before and after therapy in the placebo group (ACh 12 <mu>g/min: +12.9 +/- 3.6 vs. +9.0 +/- 1.9 ml/min/100 ml, NS; ACh 4 8 mug/min: +20.7 +/- 3.7 vs. 19.4 +/- 2.9 ml/min/100 ml, NS). Endothelium-d ependent vasodilation improved in comparison with placebo (ACh 48 mug/min: +203 +/- 85% [cerivastatin] vs. -26 +/- 71% [placebo], p < 0.05). This impr ovement in endothelium-dependent vasodilation was no longer observed when t he nitric oxide-synthase inhibitor N(G)-monomethyl-L-arginine was coinfused (ACh 48 <mu>g/min + N(G)-monomethyl-L-arginine 4 mu mol/min -48 +/- 85% [c erivastatin]). CONCLUSIONS Short-term lipid-lowering therapy with cerivastatin can improve endothelial function and NO bioavailability after two weeks in patients wi th hypercholesterolemia. (J Am Coll Cardiol 2001;37:1351-8) (C) 2001 by the American College of Cardiology.